BIRC5 and urinary bladder cancer: Based on these results ex vivo, we have conducted phase I clinical trials assessing the adverse event and efficacy of Survivin-2B80-88 peptide vaccination in patients with advanced colorectal cancer, breast cancer, lung cancer, bladder cancer, and oral cancer [24-26].